PFE - Sangamo: Partnering A Path To The Future Of Medicine
- Genomic medicine collaborations are a valuable method of risk mitigation. They also are a source of funding which can be used to build a deeper pipeline.
- Sangamo is leveraging many pharmaceutical leaders to help fund an emerging pipeline of owned programs.
- Cash flows from collaborations are rarely included in valuation or dilution models but that may be starting to change.
- Science Translational Medicine reported on studies using dead Cas9 and zinc fingers for pain management at UCSD which led to formation of Navega Therapeutics.
- Sanofi provided an early look at the sickle cell program. Three patients treated without recurrence of previous SCD symptoms up to 52 weeks.
For further details see:
Sangamo: Partnering A Path To The Future Of Medicine